Kondaveeti Satish Srinivas, C V Divyambika, John Christopher, M Manickavasagam, S Rajendiran
Department of Radiation Oncology, Sri Ramachandra Medical College and Research Institute, Porur, Chennai, India. Email: cvdivyambika@ sriramachandra.edu.in
Asian Pac J Cancer Prev. 2018 Nov 29;19(11):3099-3103. doi: 10.31557/APJCP.2018.19.11.3099.
Background: A troublesome and usually unavoidable consequence of Head and Neck chemo radiation is oral mucositis which decreases patients’ compliance and negatively influences the outcome of therapy by increasing overall treatment time. Currently, no single effective recommended treatment exists for this problem and a variety of supportive care measures have been practiced with limited benefits. This study was done to evaluate the therapeutic benefit of Placentrex in the management of oral mucositis seen in oral cancer patients undergoing treatment with concurrent chemoradiation. Methodology: This study was carried out, as a retrospective analysis, on oral cancer patients undergoing concurrent chemoradiation with weekly Cisplatin regimen treated between Oct 2015 and July 2017. All the patients received 2ml of Inj Placentrex, once daily administered intramuscularly for 4 weeks, NSAIDs, topical analgesics, and mouth wash as treatment for oral mucositis. The results were compared with a historical control group of 40 oral cancer patients who had received treatment prior to the study period without receiving Inj Placentrex as a part of oral mucositis management. Results: Over 60% of the patients in both groups were older than 60 years of age. Buccal mucosa was the predominant sub site of the investigated cancer type. The addition of placentrex resulted in delay in the progression of mucositis, reduction of treatment breaks, regression of pain, and improvement of dysphagia while leading to no adverse effects (p<0.05). Conclusion: Placentrex appears to be a beneficial therapeutic option for the management of concurrent chemo-radiation induced acute oral mucositis in oral cancer patients.
头颈部放化疗一个棘手且通常不可避免的后果是口腔黏膜炎，这会降低患者的依从性，并通过延长总体治疗时间对治疗结果产生负面影响。目前，针对这个问题尚无单一有效的推荐治疗方法，并且已经实施了多种支持性护理措施，但效果有限。本研究旨在评估胎盘多肽注射液在接受同步放化疗的口腔癌患者口腔黏膜炎管理中的治疗效果。方法：本研究作为一项回顾性分析，对2015年10月至2017年7月期间接受每周顺铂方案同步放化疗的口腔癌患者进行。所有患者均接受2ml胎盘多肽注射液，每日一次肌肉注射，共4周，同时使用非甾体抗炎药、局部镇痛药和漱口水治疗口腔黏膜炎。将结果与40例在研究期间之前接受治疗但未接受胎盘多肽注射液作为口腔黏膜炎管理一部分的口腔癌患者的历史对照组进行比较。结果：两组中超过60%的患者年龄超过60岁。颊黏膜是所研究癌症类型的主要亚部位。添加胎盘多肽注射液导致黏膜炎进展延迟、治疗中断减少、疼痛减轻和吞咽困难改善，且未产生不良反应（p<0.05）。结论：胎盘多肽注射液似乎是口腔癌患者同步放化疗诱导的急性口腔黏膜炎管理的有益治疗选择。
